Hepatocellular Carcinoma

Description

In what new setting could Roche's Tecentriq + Avastin combination consolidate its standard-of-care position for the first-line treatment of immunotherapy-eligible HCC patients? Why are oncologists optimistic about the read out of the EMERALD-2 trial of AstraZeneca's Imfinzi + Roche's Avastin combination and why might EMERALD-3 trial data cause concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Executive summary (8)

Current and future treatment algorithm for HCC

Research objectives (2)

Immunotherapy (80)

Approved drugs (57)
- Tecentriq (atezolizumab; Roche) + Avastin (bevacizumab; Roche) (12)
- Opdivo (nivolumab; Bristol Myers Squibb) + Yervoy (ipilimumab; Bristol Myers Squibb) (14)
- Keytruda (pembrolizumab; Merck & Co.) (19)
- Imfinzi (durvalumab; AstraZeneca) + Imjudo (tremelimumab; AstraZeneca) (12)
Late-stage pipeline drugs (23)
- Tislelizumab (BeiGene/Novartis) (7)
- Camrelizumab (Jiangsu Hengrui) (5)
- Jemperli (dostarlimab; GSK) + cobolimab (GSK) (5)
- Libtayo (cemiplimab; Regeneron) (6)

Tyrosine kinase inhibitors (33)

Approved drugs (33)
- Nexavar (sorafenib; Bayer) (8)
- Lenvima (lenvatinib; Eisai/Merck & Co) (10)
- Stivarga (regorafenib; Bayer) (9)
- Cabometyx (cabozantinib; Exelixis/Ipsen) (6)

VEGFR inhibitors (4)

Approved drugs (4)
- Cyramza (ramucirumab; Lilly) (4)

Other mechanisms of action (31)

Early-stage pipeline drugs (31)
- Fotivda (tivozanib; AVEO Oncology) (6)
- Namodenoson (Can-Fite BioPharma) (5)
- GT90001 (Kintor Pharmaceutical) (5)
- ARTEMIS T-cell therapy (Eureka Therapeutics) (5)
- MTL-CEBPA (MiNA Therapeutics) (5)
- Fostroxacitabine bralpamide/fostrox (Medivir) (5)